Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
  • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
  • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
  • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins

Definitions

• the invention relates to new prostacyclin derivatives, processes for their preparation and their use as medicaments,
• Prostacyclin (PGI 2 ), one of the main factors in platelet aggregation, has a dilating effect on various blood vessels (Science 196, 1072) and could therefore be considered as a means of lowering blood pressure.
• PGI 2 does not have the stability required for a drug. Its half-life is only a few minutes at physiological pH values and at room temperature.
• DE-OS 30 35 454 describes chemically stable and biologically active 7-oxopros tacyclines.
• the compounds according to the invention inhibit platelet aggregation and have a hypotensive and bronchodilatory effect. They also have a cytoprotective effect on the heart, liver, stomach and kidney and inhibit gastric acid secretion.
• the invention relates to 7-oxoprostacyclins of the general formula I.
• W is one or a group in which the OH group can each be esterified with a benzoyl or alkanoic acid radical with 1-4 C atoms or can be etherified with a tetrahydropyranyl, tetrahydrofuranyl, alkoxyalkyl or trialkylsilyl radical, where the free or suppurated OH group can be in the ⁇ or ⁇ position,
• R 2 is a straight or branched chain alkyl group with 1-6
• R 5 is a hydroxyl group which can be esterified with an alkanic acid radical having 1-4 C atoms or etherified with a tetrahydropyranyl, tetrahydrofuranyl, alkoxyalkyl or trialkylsilyl radical,
• R 6 and R 7 is hydrogen or a straight or verzweigtketti ⁇ ge alkyl group having 1-4 carbon atoms or R 6 and R 7 eemeinsam a trimethylene group, R 8 and R 9 together are a bond or hydrogen or a straight or branched chain alkyl group having 1-4 carbon atoms and, if R 3 represents hydrogen, the salts thereof with physiologically compatible bases.
• the alkyl group R 3 is straight or branched alkyl groups with 1-10 C atoms, such as methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, heptyl, hexyl, decyl.
• the alkyl groups R 3 can optionally be substituted 1 to more times by halogen atoms, alkoxy groups with 1-4 C atoms, optionally substituted aryl groups, dialkylamines and trialkylammonium with 1-4 C atoms.
• Preferred alkyl groups are those which are monosubstituted. Examples of substituents are fluorine, chlorine or bromine atoms, phenyl, dimethylamine, methoxy, ethoxy.
• Preferred alkyl groups R 3 are those with 1-4 C atoms, such as methyl, ethyl, propyl, dimethylaminopropyl, isobutyl and butyl.
• Suitable aryl groups R 3 are both substituted and unsubstituted aryl groups, such as, for example, phenyl, 1-naphthyl and 2-naphthyl, which can each be substituted by 1-3 halogen atoms, one phenyl group, 1-3 alkyl groups, each with 1-4 C. -Atoms, a chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, hydroxy or alkoxy group with 1-4 C atoms.
• the substituents in the 3- and 4-position on the phenyl ring are preferred, for example by fluorine, chlorine, alkoxy or trifluoromethyl or in the 4-position by hydroxy.
• the cycloalkyl group R 3 in the ring 4-10 preferably
• the rings can be substituted by alkyl groups with 1-4 carbon atoms. Examples include cyciopentyl, cyciohexyl, methylcyclohexyl and adamantyl.
• Suitable heterocyclic groups R 3 are 5- and 6-membered heterocycles, of which those with a heteroatom, such as nitrogen, oxygen or sulfur, are particularly preferred. Examples include: 2-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and others.
• Suitable acid residues R 4 are physiologically compatible acid residues.
• Preferred acids are organic carboxylic acids and sulfonic acids with 1-15 carbon atoms, which belong to the aliphatic, cyclo-aliphatic, aromatic, aromatic-aliphatic and heterocyclic series. These acids can be saturated, unsaturated and / or polybasic and / or substituted in the usual way. Examples of the substituents are alkyl, hydroxyl, alkoxy, oxo or amino groups or halogen atoms.
• Examples include the following carboxylic acids: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, caproic acid, oenanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecyl acid, myristic acid, pentadecyl acid, diethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid, trimethyl acetic acid
• sulfonic acids are methanesulfonic acid, ethanesulfonic acid, isopropanesulfonic acid, ⁇ -chloroethanesulfonic acid, butanesulfonic acid, cyclopentanesulfonic acid, cyclohexanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, p-chlorobenzenesulfonic acid, N, N-dimethylaminosulfonic acid, N, N-diethylaminosulfonic acid, (N, N-diethylaminosulfonic acid, (N) -chloroethyl) -aminosulfonic acid, N, N-diisobutylaminosulfonic acid, N, N-dibutylaminosulfonic acid, pyrrolidino, piperidin
• the hydroxyl groups R 5 and in W can be functionally modified, for example by etherification or esterification, it being possible for the free or modified hydroxyl groups in W to be ⁇ - or ⁇ -permanent, and with free hydroxyl groups being preferred.
• the radicals known to the person skilled in the art are suitable as ether and acyl radicals. Easily removable ether residues such as, for example, the tetrahydropyranyl, tetrahydrofuranyl, ⁇ -ethoxyethyl, trimethylsilyl, dimethyl-tert-butylsilyl and tribenzylsilyl residue are preferred.
• Suitable acyl radicals are C 1 -C 4 alkanoyl radicals, such as, for example, acetyl, propionyl, butyryl or benzoyl.
• Suitable alkyl groups R 2 are straight-chain and branched-chain alkyl radicals with 1-6 C atoms. Examples include methyl, ethyl, propyl, butyl, isobutyl, tert. -Butyl, pentyl, hexyl. Among the alkyl radicals R 2 , those with 1-4 C atoms are particularly preferred.
• Suitable alkyl groups R 6 , R 7 , R 8 and R 9 are straight-chain or branched-chain alkyl radicals having 1-4 C atoms, as have already been mentioned for R 2 .
• alkali hydroxides such as sodium and potassium hydroxide
• alkaline earth hydroxides such as calcium hydroxide
• ammonia amines, such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, tris (hydroxymethyl) methylamine, etc.
• the invention further relates to a process for the preparation of the 7-oxoprostacyclins of the general formula I according to the invention, characterized in that a compound of the general formula II
• n, R 1 , R 2 , R 5 , R 6 , R 7 , R 8 , R 9 A and W have the meanings given above, oxidized with selenium dioxide.
• reaction of the compound of general formula II with selenium dioxide is carried out at temperatures of 20-140 ° C, preferably at 50-120 ° C, in an organic solvent, preferably dioxane or tert. -Butanol in 0.5-10 hours under inert gas (such as N 2 or Ar) and with stirring, optionally with the addition of an amine base, such as pyridine or hexamethyldisilazane.
• the saponification of the 7-oxoprostacycline esters is carried out according to the methods known to the person skilled in the art, for example with basic catalysts.
• the ester group, in which R 3 represents an alkyl group with 1-10 C atoms is introduced by the methods known to the person skilled in the art.
• the carboxy compounds are reacted, for example, with diazo hydrocarbons in a manner known per se.
• the esterification with diazo hydrocarbons takes place, for example, by mixing a solution of the diazo hydrocarbon in an inert solvent, preferably in diethyl ether, with the carboxy compound in the same or in another inert solvent, such as, for example, methylene chloride.
• Diazoalkanes are either known or can be prepared by known methods [Org. Reactions Vol. 8, pages 389-394 (1954)].
• ester group OR 3 for R 1 in which R 3 represents a substituted or unsubstituted aryl group, takes place according to the methods known to the person skilled in the art.
• the carboxy compounds are reacted with the corresponding arylhydroxy compounds with dicyclohexylcarbodiimide in the presence of a suitable base, for example pyridine or triethylamine, in an inert solvent.
• a suitable base for example pyridine or triethylamine
• Suitable solvents are methylene chloride, ethylene chloride, chloroform, ethyl acetate, tetrahydrofuran, preferably chloroform.
• the reaction is carried out at temperatures between -30 ° C and + 50 ° C, preferably at + 10 ° C.
• the 7-oxopros tacyclin derivatives of the general formula I with R 3 in the meaning of a hydrogen atom can be converted into salts with suitable amounts of the corresponding inorganic bases with neutralization.
• suitable amounts of the corresponding inorganic bases with neutralization For example, when the corresponding PG acids are dissolved in water which contains the stoichiometric amount of the base, after evaporating off the water or after adding a water-miscible solvent, for example alcohol or acetone, the solid inorganic salt is obtained.
• an araine salt which is usually carried out, the prostacyclic acid is dissolved, for example, in a suitable solvent, for example ethanol, acetone, acetonitrile, diethyl ether or benzene, and at least the stoichiometric amount of the amine is added to this solution.
• a suitable solvent for example ethanol, acetone, acetonitrile, diethyl ether or benzene
• the salt is usually obtained in solid form or is isolated in a conventional manner after evaporation of the solvent.
• the functional modification of the free OH groups takes place according to the methods known to the person skilled in the art.
• the reaction is carried out, for example, with dihydropyran in methylene chloride, benzene or chloroform using an acidic catalyst such as POCl 3 , p-toluenesulfonic acid or anhydrous mineral acids.
• the dihydropyran is used in excess, preferably in 2 to 10 times the theoretical amount.
• the reaction is usually complete after 15-30 minutes at 0 ° C to 30 ° C.
• a functionally modified OH group is released to the compounds of the general formula I by known methods.
• the ether protection groups are split off in an aqueous solution of an organic acid, such as, for example, acetic acid, propionic acid and the like. or in an aqueous solution of an inorganic acid, such as hydrochloric acid.
• a water-miscible inert organic solvent is advantageously added.
• Suitable organic solvents are, for example, alcohols, such as methanol and ethanol, and ethers, such as dimethoxyethane, dioxane and tetrahydrofuran. Tetrahydrofuran is preferred.
• the cleavage is preferably carried out at temperatures between 20 ° C and 80 ° C.
• the silyl ether protecting groups are split off, for example, with tetrabutylammonium fluoride or with KF in the presence of a crown ether.
• Suitable solvents are, for example, tetrahydrofuran, diethyl ether, dioxane, methylene chloride, etc.
• the cleavage is preferably carried out at temperatures between 0 ° C. and 80 ° C.
• the acyl groups are saponified, for example, with alkali or alkaline earth carbonates or hydroxides in an alcohol or the aqueous solution of an alcohol.
• Aliphatic alcohols such as, for example, methanol, ethanol, butanol, etc., preferably methanol, are suitable as alcohols.
• Potassium and sodium salts may be mentioned as alkali carbonates and hydrides, but the potassium salts are preferred.
• Suitable alkaline earth carbonates and hydroxides are, for example, suitable calcium carbonate, calcium hydroxide and barium carbonate. The reaction takes place at -10 ° C to 70 ° C, preferably at 25 ° C.
• R 4 has the meaning given above, optionally with the addition of a tertiary amine, such as triethylamine or pyridine.
• the reaction can be carried out without a solvent or in an inert solvent, preferably acetonitrile, tetrahydrofuran, acetone, dimethylacetamide, methylene chloride, diethyl ether, benzene, toluene, dimethyl sulfoxide, at temperatures above or below room temperature, for example between -80 ° C. to 100 ° C. preferably at 0 ° C to 30 ° C.
• the compounds of general formula II which serve as starting material can be prepared, for example, by using a known prostaglandin F derivative of general formula III in a manner known per se
• Free hydroxyl groups can then optionally be protected by esterification, etherification or silylation.
• esterification etherification or silylation.
• the reaction of the compounds of the general formula IV to the compounds of the general formula II can be carried out, for example, with 1,5-diazabicyclo [3,4,0] nonen-5 (DBN) or 1,5-diazabycyclo [5,4,0] - undecen-5 (DBU) in an inert solvent such as benzene, toluene, tetrahydrofuran etc. or with sodium methylate in methanol.
• the hydrogen halide is carried out at temperatures between 0 ° C and 120 ° C, preferably at 20-60 ° C.
• end products which contain free hydroxyl groups in the prostane residue are ultimately desired, it is more expedient indicates starting products in which these are temporarily protected by preferably easily removable ether or acyl residues.
• the compounds of this invention have hypotensive and bronchodilatory effects. They are also suitable for inhibiting platelet aggregation.
• the new prostacyclin derivatives of the formula I are valuable pharmaceutical active ingredients.
• they have a higher specificity and, above all, a substantially longer activity compared to corresponding prostaglandins.
• Compared to PGI 2 they are characterized by greater stability.
• the high tissue specificity of the new prostaglandins can be seen when examining smooth muscle organs, such as the guinea pig ileum or the isolated rabbit trachea, where a significantly lower stimulation is observed than when applying natural prostaglandins of the E, A or F type.
• the new prostaglandins have the properties typical of prostacyclins, such as lowering peripheral arterial and coronary vascular resistance, inhibiting platelet aggregation and dissolving platelet thrombi, myocardial cytoprotection and thus lowering systemic blood pressure without simultaneously reducing stroke volume and coronary blood flow; Treatment of stroke, prophylaxis and therapy of coronary heart diseases, coronary thrombosis, herbar infarction, peripheral arterial diseases, arteriosclerosis and thrombosis, therapy of shock, inhibition of bronchoconstriction, inhibition of gastric acid secretion and cytoprotection of the gastric and intestinal mucosa; anti-allergic properties, Lowering pulmonary vascular resistance and pulmonary blood pressure, promoting kidney blood flow, use instead of heparin or as an adjuvant for dialysis of haemofiltration, preservation of blood plasma consumption, especially of preserved platelets, inhibition of labor pains, treatment of pregnancy toxicity, increased cerebral circulation, etc.
• the new prostaglandin analogues also
• the dose of the compounds is 1-1,500 ⁇ g / kg / day when administered to the human patient.
• the unit dose for the pharmaceutically acceptable carrier is 0.01-100 mg.
• the compounds according to the invention show a greater hypotensive and longer-lasting effect than PGE 2 and PGA 2 , without triggering cardiac arrhythmias like PGE 2 or PGA 2 .
• the compounds according to the invention show, compared to PGE 2 and PGA 2, a stronger and considerably longer lasting reduction in blood pressure without affecting other smooth-muscular organs or organ functions.
• Sterile, injectable, aqueous or oily solutions are used for parenteral administration.
• parenteral administration for example, tablets, coated tablets or
• the invention thus also relates to medicaments based on the compounds of the general formula I and customary auxiliaries and carriers.
• the active compounds according to the invention are intended to serve in conjunction with the auxiliaries known and customary in galenics, for example for the production of hypotensive agents.
• the residue is dissolved in dichloromethane and dried with magnesium sulfate.
• the residue that remains after filtering off the drying agent and removing the solvent is purified by chromatography on silica gel using a dichloromethane / acetone system. 4.23 g, corresponding to 81.6% of theory, are obtained.
• a solution of 5.89 g of sodium hydrogen carbonate in 85 ml of water is added to a solution of 2.68 g of the methyl ester obtained according to Example 1g in 60 ml of diethyl ether. With vigorous stirring, the mixture is cooled to 0 ° and a solution of 2.53 g of iodine in 35 ml of diethyl ether is added dropwise. The mixture is stirred at 0 ° for 2 hours. The reaction solution is placed in a separatory funnel, the phases are separated and the ethereal phase is washed once with 5% sodium thiosulfate solution and twice with water. The combined water phases are extracted with diethyl ether. The organic phase is dried with magnesium sulfate.
• IR 1760 cm -1 , 1720 cm -1 , 1700 cm -1 , 1640 cm -1 , 1460 cm -1 .
• IR 3400 (broad), 1710, 1650, 1460, 1360 cm -1 .
• IR 3400 (broad), 1710, 1650, 1460, 1360 cm -1 .
• IR 3400 (broad), 1710, 1640, 1350 cm -1 .

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Furan Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6214168

Family Applications (1)

Country Status (5)

Cited By (2)

Citations (1)

• 1983
  • 1983-11-10 DE DE19833340988 patent/DE3340988A1/de not_active Ceased
• 1984
  • 1984-11-08 EP EP84904100A patent/EP0163672B1/de not_active Expired - Lifetime
  • 1984-11-08 JP JP59504339A patent/JPS61500551A/ja active Granted
  • 1984-11-08 WO PCT/DE1984/000238 patent/WO1985002187A1/de not_active Ceased
  • 1984-11-08 DE DE8484904100T patent/DE3484597D1/de not_active Expired - Lifetime
  • 1984-11-09 IT IT23507/84A patent/IT1177142B/it active

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events